Jeffrey G. Lamothe - 02 Mar 2024 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
EVP, COO
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Issuer symbol
APVO
Transactions as of
02 Mar 2024
Net transactions value
$0
Form type
4
Filing time
05 Mar 2024, 16:12:11 UTC
Previous filing
30 Jan 2024
Next filing
19 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +5,500 +19% 33,837 02 Mar 2024 Direct F1
transaction APVO Common Stock Options Exercise +3,667 +11% 37,504 03 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -5,500 -33% $0.000000 11,000 02 Mar 2024 Common Stock 5,500 Direct F1, F2
transaction APVO Restricted Stock Unit Options Exercise $0 -3,667 -50% $0.000000 3,667 03 Mar 2024 Common Stock 3,667 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On March 3, 2023, the reporting person was granted 16,500 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
F3 On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.